JP2023553697A5 - - Google Patents
Info
- Publication number
- JP2023553697A5 JP2023553697A5 JP2023536866A JP2023536866A JP2023553697A5 JP 2023553697 A5 JP2023553697 A5 JP 2023553697A5 JP 2023536866 A JP2023536866 A JP 2023536866A JP 2023536866 A JP2023536866 A JP 2023536866A JP 2023553697 A5 JP2023553697 A5 JP 2023553697A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- isvd
- specifically binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026020000A JP2026103881A (ja) | 2020-12-18 | 2026-02-10 | グリピカン－３およびｔ細胞受容体を標的とする免疫グロブリン単一可変ドメインを含むポリペプチド |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063127224P | 2020-12-18 | 2020-12-18 | |
| US63/127,224 | 2020-12-18 | ||
| EP20306633.7 | 2020-12-21 | ||
| EP20306633 | 2020-12-21 | ||
| PCT/EP2021/086559 WO2022129560A1 (en) | 2020-12-18 | 2021-12-17 | Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026020000A Division JP2026103881A (ja) | 2020-12-18 | 2026-02-10 | グリピカン－３およびｔ細胞受容体を標的とする免疫グロブリン単一可変ドメインを含むポリペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023553697A JP2023553697A (ja) | 2023-12-25 |
| JP2023553697A5 true JP2023553697A5 (enExample) | 2024-10-25 |
| JP7820383B2 JP7820383B2 (ja) | 2026-02-25 |
Family
ID=79283159
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023536866A Active JP7820383B2 (ja) | 2020-12-18 | 2021-12-17 | グリピカン－３およびｔ細胞受容体を標的とする免疫グロブリン単一可変ドメインを含むポリペプチド |
| JP2026020000A Pending JP2026103881A (ja) | 2020-12-18 | 2026-02-10 | グリピカン－３およびｔ細胞受容体を標的とする免疫グロブリン単一可変ドメインを含むポリペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026020000A Pending JP2026103881A (ja) | 2020-12-18 | 2026-02-10 | グリピカン－３およびｔ細胞受容体を標的とする免疫グロブリン単一可変ドメインを含むポリペプチド |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11932702B2 (enExample) |
| EP (1) | EP4262985A1 (enExample) |
| JP (2) | JP7820383B2 (enExample) |
| KR (1) | KR20230123495A (enExample) |
| AU (1) | AU2021399955A1 (enExample) |
| CA (1) | CA3205422A1 (enExample) |
| CO (1) | CO2023009231A2 (enExample) |
| IL (1) | IL303783A (enExample) |
| MX (1) | MX2023007308A (enExample) |
| WO (1) | WO2022129560A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3141978A1 (en) | 2011-06-23 | 2012-12-27 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| HRP20191800T1 (hr) * | 2015-05-13 | 2019-12-27 | Ablynx N.V. | Polipeptidi koji regrutiraju t stanice koji se temelje na tcr alfa/beta reaktivnosti |
| CN119630705A (zh) * | 2022-06-14 | 2025-03-14 | 阿布林克斯有限公司 | 靶向t细胞受体的免疫球蛋白单可变结构域 |
| US20260191905A1 (en) * | 2022-12-01 | 2026-07-09 | Modernatx, Inc. | Gpc3-specific antibodies, binding domains, and related proteins and uses thereof |
| US20240415974A1 (en) | 2022-12-23 | 2024-12-19 | Ablynx N.V. | Protein-based conjugation carriers |
| KR20260068087A (ko) | 2023-09-04 | 2026-05-13 | 사노피 | 글리피칸-3-발현 종양의 치료에 사용하기 위한 폴리펩티드 |
| WO2025061919A1 (en) * | 2023-09-22 | 2025-03-27 | Ablynx Nv | Bi- and multivalent albumin binders |
| WO2025262150A2 (en) | 2024-06-18 | 2025-12-26 | Ablynx Nv | Antibody-recruiting molecules |
| WO2026145795A1 (zh) * | 2025-01-06 | 2026-07-09 | 湖南中晟全肽生物科技股份有限公司 | 一种gpc3靶向结合多肽及其药物偶联物与应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| DK1027439T3 (da) | 1997-10-27 | 2010-05-10 | Bac Ip Bv | Multivalente antigenbindende proteiner |
| NZ540194A (en) | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| AU2005256113B2 (en) | 2004-07-09 | 2011-02-10 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody |
| AU2006249144B2 (en) | 2005-05-18 | 2011-11-17 | Ablynx Nv | Improved NanobodiesTM against Tumor Necrosis Factor-alpha |
| AU2007237501A1 (en) | 2006-04-14 | 2007-10-25 | Ablynx N.V. | DP-78-like nanobodies |
| JP2010500876A (ja) | 2006-08-18 | 2010-01-14 | アブリンクス エン．ヴェー． | Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド |
| AU2008275985B2 (en) * | 2007-07-17 | 2013-09-19 | E. R. Squibb & Sons, L.L.C. | Monoclonal antibodies against Glypican-3 |
| AU2010336277B2 (en) | 2009-12-25 | 2015-02-19 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide modification method for purifying polypeptide multimers |
| CA3141978A1 (en) | 2011-06-23 | 2012-12-27 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| LT3466972T (lt) | 2011-06-23 | 2026-06-25 | Ablynx Nv | Serumo albuminą surišantys baltymai |
| LT3248986T (lt) | 2014-05-16 | 2022-03-25 | Ablynx Nv | Imunoglobulino kintami domenai |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| HRP20191800T1 (hr) | 2015-05-13 | 2019-12-27 | Ablynx N.V. | Polipeptidi koji regrutiraju t stanice koji se temelje na tcr alfa/beta reaktivnosti |
| HUE057241T2 (hu) | 2015-11-13 | 2022-04-28 | Ablynx Nv | Javított, szérumalbumint kötõ immunoglobulin variábilis domének |
| AU2016357460B2 (en) | 2015-11-18 | 2023-07-27 | Ablynx Nv | Improved serum albumin binders |
| EP3431102A4 (en) | 2016-03-14 | 2019-09-25 | Chugai Seiyaku Kabushiki Kaisha | CELL DAMAGING THERAPEUTIC MEDICAMENT FOR USE IN CANCER THERAPY |
| US11840569B2 (en) * | 2016-11-16 | 2023-12-12 | Ablynx N.V. | T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta |
| WO2018104444A1 (en) | 2016-12-07 | 2018-06-14 | Ablynx Nv | Improved serum albumin binding immunoglobulin single variable domains |
| EP3571224B1 (en) | 2017-01-17 | 2024-08-07 | Ablynx NV | Improved serum albumin binders |
| EP4442709A3 (en) | 2017-01-17 | 2024-12-25 | Ablynx NV | Improved serum albumin binders |
-
2021
- 2021-12-17 CA CA3205422A patent/CA3205422A1/en active Pending
- 2021-12-17 US US17/553,908 patent/US11932702B2/en active Active
- 2021-12-17 IL IL303783A patent/IL303783A/en unknown
- 2021-12-17 MX MX2023007308A patent/MX2023007308A/es unknown
- 2021-12-17 JP JP2023536866A patent/JP7820383B2/ja active Active
- 2021-12-17 AU AU2021399955A patent/AU2021399955A1/en active Pending
- 2021-12-17 KR KR1020237024067A patent/KR20230123495A/ko active Pending
- 2021-12-17 WO PCT/EP2021/086559 patent/WO2022129560A1/en not_active Ceased
- 2021-12-17 EP EP21839545.7A patent/EP4262985A1/en active Pending
-
2023
- 2023-07-12 CO CONC2023/0009231A patent/CO2023009231A2/es unknown
-
2026
- 2026-02-10 JP JP2026020000A patent/JP2026103881A/ja active Pending